RG6496
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 25, 2025
POINT-HD: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Hoffmann-La Roche
New P1 trial • Huntington's Disease • Movement Disorders
1 to 1
Of
1
Go to page
1